Clinical Epidemiology Program, Veterans Affairs Medical Center, White River Junction, Vermont.
Department of Psychiatry, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.
J Infect Dis. 2018 May 5;217(11):1718-1727. doi: 10.1093/infdis/jiy088.
We examined whether a high-dose inactivated influenza vaccine was more efficacious in preventing hospitalizations than a standard-dose vaccine in the Veterans Health Administration (VHA) senior population.
This study estimated the relative vaccine effectiveness (rVE) of high dose versus standard dose using a retrospective cohort of VHA patients 65 years of age or older in the 2015-2016 influenza season. To adjust for measured confounders, we matched each high-dose recipient with up to 4 standard-dose recipients vaccinated at the same location within a 2-week period and having 2 or more pre-existing medical comorbidities. We used the previous event rate ratio method (PERR), a type of difference-in-differences analysis, to adjust for unmeasured confounders.
We evaluated 104965 standard-dose and 125776 high-dose recipients; matching decreased the population to 49091 standard-dose and 24682 high-dose recipients. The matched, PERR-adjusted rVE was 25% (95% confidence interval [CI], 2%-43%) against influenza- or pneumonia-associated hospitalization, 7% (95% CI, -2% to 14%) against all-cause hospitalization, 14% (95% CI, -8% to 32%) against influenza- or pneumonia-associated outpatient visit, 5% (95% CI, 2%-8%) against all-cause outpatient visit, and 38% (95% CI, -5% to 65%) against laboratory-confirmed influenza.
In protecting senior VHA patients against influenza- or pneumonia-associated hospitalization, a high-dose influenza vaccine is more effective than a standard-dose vaccine.
我们研究了在退伍军人健康管理局(VHA)老年人群中,高剂量灭活流感疫苗相对于标准剂量疫苗在预防住院方面是否更有效。
本研究使用 2015-2016 年流感季节 VHA 年龄在 65 岁及以上的患者回顾性队列,估计高剂量与标准剂量的相对疫苗有效性(rVE)。为了调整测量混杂因素,我们将每位高剂量接受者与在 2 周内同一地点接种疫苗且有 2 种或更多预先存在的合并症的多达 4 名标准剂量接受者相匹配。我们使用先前的事件率比方法(PERR),一种差异中的差异分析,来调整未测量的混杂因素。
我们评估了 104965 名标准剂量和 125776 名高剂量接受者;匹配将人群减少到 49091 名标准剂量和 24682 名高剂量接受者。匹配后,PERR 调整的 rVE 为 25%(95%可信区间,2%-43%),可预防流感或肺炎相关住院治疗;7%(95%可信区间,-2%至 14%)可预防全因住院治疗;14%(95%可信区间,-8%至 32%)可预防流感或肺炎相关门诊就诊;5%(95%可信区间,2%-8%)可预防全因门诊就诊;38%(95%可信区间,-5%至 65%)可预防实验室确诊的流感。
在保护 VHA 老年患者免受流感或肺炎相关住院治疗方面,高剂量流感疫苗比标准剂量疫苗更有效。